TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy-Reference-Cited by-同舟云学术

TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy

Published:2018-10-31 Issue:4 Volume:54 Page:339-346
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Iio Etsuko,Matsuura Kentaro,Shimada Noritomo,Atsukawa Masanori,Itokawa Norio,Abe Hiroshi,Kato Keizo,Takaguchi Koichi,Senoh Tomonori,Eguchi Yuichiro,Nomura Hideyuki,Yoshizawa Kai,Kang Jong-Hon,Matsui Takeshi,Hirashima Noboru,Kusakabe Atsunori,Miyaki Tomokatsu,Fujiwara Kei,Matsunami Kayoko,Tsutsumi Susumu,Iwakiri Katsuhiko,Tanaka Yasuhito

Funder

Japan Agency for Medical Research and Development

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-018-1526-3.pdf

Reference35 articles.

1. Ogawa E, Furusyo N, Nomura H, et al. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. J Gastroenterol. 2017;52:845–54.

2. Iio E, Shimada N, Takaguchi K, et al. Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy. Hepatol Res. 2017;47:1308–16.